Aerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
September 17, 2015 10:09 AM EDTCanaccord Genuity reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), and raised the price target to $44.00 (from $40.00), following announced Rocket 2 data. It's clear that the drug has clinically meaningful activity in glaucoma and in Canaccord's opinion is very approvable.
Analyst Corey Davis commented,... More
RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
September 17, 2015 9:00 AM EDTRBC Capital lifts its price target on Outperform-rated Aerie Pharmaceuticals (Nasdaq: AERI) from $31 up to $44 following news that Rhopressa Phase 3 met its primary endpoint.
Analyst Michael J. Yee noted the following key points:
Safety is in-line and not too different from Rocket 1. Hyperemia is a known side effect and it was higher in the BID than the QD arm; however, of the 35% with increased redness, 83% scored as mild... MoreAerie Pharma (AERI) PT Raised to $48 at Brean Capital
September 17, 2015 6:59 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $48.00 (from $33.00), saying Rocket 2 is positive for Rhopressa.
Yang commented, "While approvals on Rhopressa and Roclatan are not expected until the 2017-2018 time... More
Aerie Pharma (AERI) PT Raised to $45 at Needham & Company
September 17, 2015 6:22 AM EDTNeedham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $45.00 (from $27.00) after the company reported top-line results from ROCKET-2, where Rhopressa met the primary endpoint by demonstrating non-inferiority in IOP-lowering vs. timolol.
Belanger... More
Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
September 16, 2015 4:04 PM EDTAerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa compared to timolol, the most widely used comparator. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.
Rhopressa Phase 3 Highlights for Rocket 2
Rhopressa, dosed both once-daily and twice-daily, achieved its primary... More